Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
39 hedge funds and large institutions have $68.5M invested in Eiger BioPharmaceuticals, Inc. in 2018 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 5 reducing their positions, and 11 closing their positions.
180% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 5
9% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 11
3% less funds holding
Funds holding: 40 → 39 (-1)
32% less capital invested
Capital invested by funds: $101M → $68.5M (-$32.7M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$1.92M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$976K |
| 3 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$741K |
| 4 |
Renaissance Technologies
New York
|
+$660K |
| 5 |
BlackRock
New York
|
+$513K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$5.36M |
| 2 |
DM
Deerfield Management
New York
|
-$4.18M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.09M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
-$1.46M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$611K |
EIGR Hedge Fund Activity: Q1 2018 in Review
39 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q1 2018, worth a combined $68.5M — down 32% from $101M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of EIGR and 10 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 14 added.
The largest buyer was 683 Capital Management, opening a new position worth an estimated $1.92M. The largest seller was Armistice Capital, exiting entirely with an estimated $5.36M sold.
- 39 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q1 2018, down from 40 in Q4 2017.
- Funds reported $68.5M of Eiger BioPharmaceuticals, Inc. stock for Q1 2018, down 32% quarter-over-quarter.
- 10 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q1 2018 and 11 closed out, a net change of -1 holder.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q1 2018 was 683 Capital Management, an estimated $1.92M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q1 2018 was Armistice Capital, an estimated $5.36M sold.
Based on aggregated 13F filings for Q1 2018.